The U.S. Food and Drug Administration (FDA) is planning to require all new vaccines to undergo placebo-controlled trials ...

“This is a clear and deliberate shift,” Corbett says.

Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant Sanofi’s Indian ...

Dr Reddy’s & Sanofi Healthcare expand partnership to unveil Beyfortus, a novel drug to prevent RSV in India: Our Bureau, Bengaluru Tuesday, April 29, 2025, 12:15 Hrs [IST] Dr Re ...

Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India.

Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody, nirsevimab, in a prefilled injection used ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody nirsevimab, in a prefilled injection used ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Approval granted for adults and children 12 years and older who remain symptomatic despite antihistamine treatment.